Sign in
Taking people in United StatesPhase 1

Tests angiotensin-(1-7) infusion in adults with obesity and insulin resistance

Tests whether an infusion of angiotensin-(1-7) affects insulin sensitivity in adults with obesity.

Key facts

Who runs it
Vanderbilt University
Where
Nashville, United StatesSee the site
Trial code
Registry title
Metabolic Effects of Angiotensin-(1-7)
Status
Recruiting
Phase
Phase 1
People taking part
26 people, planned
Started
Feb 2016
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Angiotensin-(1-7)
  • Saline
Record updated
22 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 60 with obesity, insulin resistance and high or borderline high blood pressure. It tests the effects of angiotensin-(1-7) on how the body handles sugar.

Age
18 to 60 years
Sex
Women and men can join.
Disease stage
Obesity with a body mass index (BMI) between 30-40 kg/m2. Insulin resistance with a HOMA2-IR score above 2.2. High blood pressure: two or more seated readings above 130/85 mmHg, or taking blood pressure medicine.
Earlier treatment
People must not have had any investigational drug in the month before the study. People must not be taking certain medicines: SNRIs, NET inhibitors, phosphodiesterase 5 inhibitors, anticoagulants, or long-term glucocorticoids (more than 7 days in a row in 1 month).
Biomarker or test result
HOMA2-IR score above 2.2.

Main reasons for not taking part

  • Pregnancy or breast-feeding
  • Type 1 or type 2 diabetes
  • Heart disease other than high blood pressure, or serious stroke-type brain vessel disease
  • Current smoker or heavy smoking history, or alcohol or drug abuse
  • Poor liver or kidney function, or anemia

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Males and females of all races between 18 and 60 years of age
  • Obesity defined as body mass index between 30-40 kg/m2
  • Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score >2.2
  • Hypertension defined by two or more properly measured seated blood pressure readings >130/85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension
  • Able and willing to provide informed consent

Who cannot take part

  • Previous allergic reaction to study medications
  • Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
  • Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors
  • Treatment with phosphodiesterase 5 inhibitors
  • Treatment with anticoagulants
  • Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
  • Treatment with any investigational drug in the 1 month preceding the study
  • Current smokers or history of heavy smoking (>2 packs/day)
  • History of alcohol or drug abuse
  • History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
  • History or presence of immunological or hematological disorders
  • Evidence of type I or type II diabetes (i.e. fasting glucose >126 mg/dl, use of anti-diabetic medications)
  • Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) > 2.0 x upper limit of normal range]
  • Impaired renal function (serum creatinine >1.5 mg/dl)
  • Anemia (hemoglobin <13.5 g/dl in males or <12.5 g/dl in females)
  • Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol)
  • Pregnancy or breast-feeding
  • Morbid obesity (BMI > 40 kg/m2)
  • Inability to give, or withdraw, informed consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United States

  • Vanderbilt University Medical CenterNashville, United StatesContact: Cynthia Laws, MSTaking people

About the trial

What the trial wants to find out

The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.

The 2 groups in the trial

  • Angiotensin-(1-7)Treatment being tested

    Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.

  • SalinePlacebo, for comparison

    Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Metabolic Effects of Angiotensin-(1-7)
Plain-language title
Tests angiotensin-(1-7) infusion in adults with obesity and insulin resistanceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT02646475, who can take part
Record updated
22 May 2026